Study Title: A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Sivapiragasam, Abirami, at sivapira@musc.edu.Study Coordinator, Gelardi, Theresa, at gelardi@musc.edu.Trial opened at the following institutions: Medical University of South Carolina